Haidong M Dong, MD, PhD

  • 13508 Citations
  • 47 Scopus h-Index
1992 …2019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 1992 2019

Filter
Review article
2019

Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy

Failing, J. J., Dudek, O. A., Marin Acevedo, J. A., Chirila, R. M., Dong, H. M., Markovic, S. N. & Dronca, R. S., Aug 1 2019, In : Future Oncology. 15, 22, p. 2645-2656 12 p.

Research output: Contribution to journalReview article

Biomarkers
Neoplasms
Sample Size
Immunotherapy
Therapeutics

Paradox-driven adventures in the development of cancer immunology and immunotherapy

Barham, W., Gicobi, J. K., Yan, Y., Dronca, R. S. & Dong, H. M., Jan 1 2019, (Accepted/In press) In : Genes and Diseases.

Research output: Contribution to journalReview article

Open Access
Immunology
Allergy and Immunology
Immunotherapy
Social Responsibility
Standard of Care
2018
26 Citations (Scopus)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

Yan, Y., Kumar, A. B., Finnes, H., Markovic, S. N., Park, S. S., Dronca, R. S. & Dong, H. M., Jan 1 2018, In : Frontiers in Immunology. 9, 1 p.

Research output: Contribution to journalReview article

Neoplasms
Radiotherapy
Therapeutics
Drug Therapy
Immunomodulation
2017
26 Citations (Scopus)

Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells

Johnson, R. M. G. & Dong, H. M., Aug 10 2017, In : Frontiers in Immunology. 8, AUG, 961.

Research output: Contribution to journalReview article

CD80 Antigens
T-Lymphocytes
Neoplasms
Antibodies
Therapeutics
2016
4 Citations (Scopus)
Immunotherapy
Melanoma
Cell Death
Biomarkers
T-Lymphocytes